Welcome to RNAnalytics on LinkedIn!

At RNAnalytics, we are redefining quality control in gene therapy with our innovative Lipid Nanoparticle (LNP) analysis kits, designed to seamlessly integrate into existing workflows. Our flagship product, the GeneVecto Analyzer, offers precise, scalable, and regulatory-compliant solutions for analyzing LNP size and encapsulation efficiency, empowering pharmaceutical labs to meet the highest industry standards.

🚀 Our Mission
We are building the next generation of analytical toolkits to accelerate RNA-based therapeutic development, ensuring faster, more accurate drug delivery for mRNA vaccines, gene therapies, and advanced biologics.

🎯 Engaging Investors and Partners
We are currently in the prototype testing phase with strong academic collaborations, positioning ourselves for rapid market entry. With a growing RNA therapeutics market projected to reach €5 billion by 2030, we invite investors and potential customers to join us in shaping the future of precision medicine.

🌍 Vision for Tomorrow
By 2030, our goal is to become the global leader in scalable LNP analysis, setting new standards in biotech QC and providing tools to revolutionize therapeutic development worldwide.

For partnerships, investments, or product inquiries, we’d love to connect.

📩 Contact:
Viktoria Enkmann, CEO
📞 +43 664 8643860
🌐 www.rnanalytics.eu

Together, let’s advance science and redefine quality control! 🌟

RNAnalytics

Org chart

Teams

Offices